Cobicistat: a guide to its use as a pharmacokinetic enhancer of atazanavir and darunavir in HIV-1 infection


    loading  Checking for direct PDF access through Ovid

Abstract

Oral cobicistat (Tybost™), a selective CYP3A inhibitor without intrinsic anti-HIV activity, is an emerging alternative to ritonavir for the pharmacokinetic enhancement of protease inhibitors (PIs) in adults with HIV-1 infection. Relative to low-dose ritonavir, cobicistat has a lower potential for drug interactions, provides bioequivalent PI exposure, is associated with noninferior virological suppression rates, has a similar tolerability profile and is more soluble, making co-formulation with antiretroviral drugs easier.

    loading  Loading Related Articles